Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Boehringer Ingelheim
Medtronic
Merck
McKinsey

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Carbavance

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Carbavance?

Carbavance is an investigational drug.

There have been 6 clinical trials for Carbavance. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2014.

The most common disease conditions in clinical trials are Infection, Pneumonia, Bacterial, and Pneumonia. The leading clinical trial sponsors are Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), Department of Health and Human Services, and Melinta Therapeutics, Inc.

There are two US patents protecting this investigational drug and twenty-eight international patents.

Recent Clinical Trials for Carbavance
TitleSponsorPhase
A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial PneumoniaMelinta Therapeutics, Inc.Phase 3
Dose-finding, Pharmacokinetics, Safety, and Tolerability of Meropenem-Vaborbactam in Pediatric Subjects With Serious Bacterial InfectionsDepartment of Health and Human ServicesPhase 1
Dose-finding, Pharmacokinetics, Safety, and Tolerability of Meropenem-Vaborbactam in Pediatric Subjects With Serious Bacterial InfectionsRempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)Phase 1

See all Carbavance clinical trials

Clinical Trial Summary for Carbavance

Top disease conditions for Carbavance
Top clinical trial sponsors for Carbavance

See all Carbavance clinical trials

US Patents for Carbavance

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Carbavance   Start Trial Cyclic boronic acid ester derivatives and therapeutic uses thereof Rempex Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
Carbavance   Start Trial Cyclic boronic acid ester derivatives and therapeutic uses thereof Rempex Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Carbavance

Drugname Country Document Number Estimated Expiration Related US Patent
Carbavance Australia 2011289615 2030-08-10   Start Trial
Carbavance Brazil 112013003045 2030-08-10   Start Trial
Carbavance Canada 2807546 2030-08-10   Start Trial
Carbavance Chile 2013000399 2030-08-10   Start Trial
Carbavance China 103180328 2030-08-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Boehringer Ingelheim
Colorcon
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.